Direct-to-consumer advertisements for HIV antiretroviral medications: A progress report

Health Affairs

Volumn 26, Issue 5, 2007, Pages 1392-1398

  Kallen, Alexander ^a   Woloshin, Steven ^b   Shu, Jennifer ^c   Juhl, Ellen ^d   Schwartz, Lisa ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Children's Medical Group   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADVERTIZING; ARTICLE; BIBLIOMETRICS; DRUG INDUSTRY; HUMAN; MASS MEDIUM; PUBLICATION; STANDARD; STATISTICS;

ADVERTISING AS TOPIC; ANTI-HIV AGENTS; BIBLIOMETRICS; DRUG INDUSTRY; HUMANS; MASS MEDIA; PERIODICALS AS TOPIC;

EID: 35148858781     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.5.1392     Document Type: Article

References (26)

1. IMS Health, "Total U.S. Promotional Spend by Type, 2006," http://imshealth.com/ims/portal/front/articleC/0,2777,6599_80402580_81493254,00. html (accessed 17 July 2007);
2. and Food and Drug Administration, "FY 2007 Budget Request Highlights Mission Priorities and Fiscal Responsibility," Press Release, 6 February 2006, http://www.fda.gov/bbs/topics/news/2006/NEW01310.html (accessed 18 June 2007).
3. M.F. Hollon, "Direct-to-Consumer Marketing of Prescription Drugs: Creating Consumer Demand," Journal of the American Medical Association 281, no. 4 (1999): 382-384;
4. and A. Chandra and M. Miller, " A Closer Look at the Concept, Historical Overview, and Value of Direct-to-Consumer Advertising of Prescription Drugs," Hospital Topics 83, no. 4 (2005): 32-36.
5. J.D. Klausner, A. Kim, and C. Kent, "Are HIV Drug Advertisements Contributing to Increases in Risk Behavior among Men in San Francisco, 2001?" AIDS 6, no. 17 (2002): 2349-2350;
6. and B. Mirken, "Advertising for AIDS Drugs: It's Everywhere Lately, but Is It Helpful?" Beta Bulletin of Experimental Treatments for AIDS (1998): 18-22.
7. D. Josefson, "FDA Warning to Manufacturers of AIDS Drugs," British Medical Journal 322, no. 7295 (2001): 1143.
8. National Health Council, Direct-to-Consumer Prescription Drug Advertising: Overview and Recommendations, January 2002, http://www.nationalhealthcouncil.org/advocacy/DTC_paper.pdf (accessed 16 July 2006).
9. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, 6 October 2005, http://www.accesstohivcare.org/ftp/ DHHS_Adult_HIV_Guidelines_6-Oct-05.pdf (accessed 18 July 2007).
10. R. Landis and G. Koch, "The Measurement of Observer Agreement for Categorical Data," Biometrics 33, no. 1 (1977): 159-174.
11. J. Murphy, Untitled letter from the FDA re: Viramune (nevirapine), 22 September 2004.
12. S. Woloshin et al., "Direct-to-Consumer Advertisements for Prescription Drugs: What Are Americans Being Sold?" Lancet 358, no. 9288 (2001): 1141-1146.
13. J. Murphy, Untitled letter from the FDA re: Kaletra (lopinavir/ritonavir) , 29 October 2004. Nelfinavir, nevirapine, and enfurvitide also included an implied survival benefit. Examples include highlighting the phrases "Viracept offers power you can live with" and "I am taking on tomorrow," and showing a spokesperson who had been "on (the drug) since 2000."
14. DHHS Panel, Guidelines for the Use.
15. FDA, "Prescription Drug Advertising," Code of Federal Regulations Title 21, Volume 4, 21CFR202.1 (Rockville, Md.: FDA, 2006).
16. S. Woloshin, L.M. Schwartz, and H.G. Welch, "The Value of Benefit Data in Direct-to-Consumer Drug Ads," Health Affairs 23 (2004):w234-w245 (published online 28 April 2004; 10.1377/hlthaff.w4.234).
17. Klausner et al., "Are HIV Drug Advertisements?"
18. Woloshin et al., "Direct-to-Consumer"; and Chandra and Miller, "A Closer Look."
19. FDA Center for Drug Evaluation and Research, "Guidance for Industry Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval" (Rockville, Md.: Office of Drug Information, 2002);
20. and K.E. Lasser et al., "Timing of New Black Box Warnings and Withdrawals for Prescription Medications," Journal of the American Medical Association 287, no. 17 (2002): 2215-2220.
21. S. Nightingale, "New Safety Information Added to Antiretroviral Package Inserts," Journal of the American Medical Association 280, no. 13 (1998): 1128;
22. and S. Nightingale, "Public Health Advisory on Protease Inhibitors for HIV Treatment," Journal of the American Medical Association 278, no. 5 (1997): 379.
23. B. Vastag, "FDA Considers Tightening Regulations for Direct-to-Consumer Advertising," Journal of the National Cancer Institute 97, no. 24 (2005): 1806-1807.
24. D. Young, "FDA Examines Direct-to-Consumer Advertising Data," American Journal of Health-System Pharmacy 60, no. 23 (2003): 2420-2421.
25. FDA, "Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements - Draft Guidance for Industry" (Rockville, Md.: FDA, 2004).
26. Woloshin et al., "The Value of Benefit Data"; and Woloshin et al., "Direct-to-Consumer."